Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-PanTumor02 Japan
jRCT2051240075Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in Nonhematologic neoplasms, endometrial cancer (EC), ovarian cancer and 2 more (5 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate. Started Jul 2024; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)ovarian cancerCervical Cancer (CC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240075.